Concord Biotech Limited (CONCORDBIO.NS) Seasonal returns chart
NiveshIQ
NSE: CONCORDBIO · Healthcare
Concord Biotech Ltd.
₹1,163.50▼ ₹82.10 (-6.59%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on CONCORDBIO. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Concord Biotech Ltd.
Concord Biotech Limited is a biopharma firm that designs, develops, manufactures, and sells active pharmaceutical ingredients (APIs) and finished formulations for immunosuppressants, oncology, and anti‑bacterial indications. The APIs segment, which includes tacrolimus, mycophenolate mofetil, and cyclosporine, accounts for roughly 60% of total revenue, while the formulations segment contributes the remaining 40%. In Q2 FY24 the company posted a consolidated net profit of ₹6,957.20 lakhs, up 12% YoY, on revenue of ₹1,108 cr, reflecting strong demand for its immunosuppressant and oncology products. Concord recently announced a 1:1 bonus issue to reward shareholders and plans to expand its fermentation‑based production capacity to meet growing global demand. The firm competes with major Indian
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹1,017 Cr +19.20% | ₹1,200 Cr +18.01% | ₹1,055 Cr -12.10% |
| EBITDA Margin | 42.44% | 42.19% | 34.83% |
| Net Profit | ₹308.10 Cr +28.30% | ₹371.64 Cr +20.62% | ₹260.91 Cr -29.80% |
| EPS | ₹29.45 | ₹35.52 | ₹24.78 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
Concord Biotech Limited (CONCORDBIO.NS) Seasonal returns chart
Concord Biotech Ltd (NSE:CONCORDBIO) (Q2 2027) Earnings Call Hig
🔒
+ 3 more stories about Concord Biotech Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q2FY27 results: revenue ₹309 Cr, PAT ₹71 Cr, EPS ₹6.65, EBITDA margin 33.8%. Growth context: revenue YoY +25.1%, PAT YoY +11.1%, revenue QoQ +20.0%, PAT QoQ +20.7%.
Management highlights product launches, approvals, therapy‑mix improvement, and strategic partnerships/joint ventures as...
FY26 (last completed FY): revenue ₹1, 055 Cr, PAT ₹261 Cr, EBITDA margin 34.8%, EPS ₹24.78. Year-on-year: revenue YoY -1...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantMore Healthcare stocks
Everything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for CONCORDBIO
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track CONCORDBIO alongside your other holdings
Unlock full CONCORDBIO research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Concord Biotech Ltd.?
NiveshIQ detects active intelligence signals for Concord Biotech Ltd. (CONCORDBIO) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Concord Biotech Ltd.?
Concord Biotech Ltd. operates in the Healthcare sector with a market capitalisation of ₹1,224,009.6L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.